tradingkey.logo

ImmuCell Corp

ICCC
查看詳細走勢圖
5.970USD
-0.170-2.77%
收盤 12/19, 16:00美東報價延遲15分鐘
54.00M總市值
21.77本益比TTM

ImmuCell Corp

5.970
-0.170-2.77%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.77%

5天

-3.86%

1月

+29.78%

6月

-21.45%

今年開始到現在

+15.92%

1年

+35.37%

查看詳細走勢圖

TradingKey ImmuCell Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

ImmuCell Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名110/158位。機構持股佔比非常高,中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ImmuCell Corp評分

相關信息

行業排名
110 / 158
全市場排名
310 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ImmuCell Corp亮點

亮點風險
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
業績高增長
公司營業收入穩步增長,連續3年增長42.68%
業績增長期
公司處於發展階段,最新年度總收入26.49M美元
估值高估
公司最新PE估值21.77,處於3年歷史高位
機構減倉
最新機構持股1.81M股,環比減少4.46%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉157.29K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.54

ImmuCell Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ImmuCell Corp簡介

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代碼ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
網址https://immucell.com/

常見問題

ImmuCell Corp(ICCC)的當前股價是多少?

ImmuCell Corp(ICCC)的當前股價是 5.970。

ImmuCell Corp 的股票代碼是什麼?

ImmuCell Corp的股票代碼是ICCC。

ImmuCell Corp股票的52週最高點是多少?

ImmuCell Corp股票的52週最高點是7.600。

ImmuCell Corp股票的52週最低點是多少?

ImmuCell Corp股票的52週最低點是4.280。

ImmuCell Corp的市值是多少?

ImmuCell Corp的市值是54.00M。

ImmuCell Corp的淨利潤是多少?

ImmuCell Corp的淨利潤為-2.16M。

現在ImmuCell Corp(ICCC)的股票是買入、持有還是賣出?

根據分析師評級,ImmuCell Corp(ICCC)的總體評級為--,目標價格為--。

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是多少

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是0.274。
KeyAI